Elicio Therapeutics Is A Clinical Stage Biotechnology Company Based In Bostonmassachusettsfounded In 2011The Company Specializes In Developing Lymph Node Targeted Immunotherapies Aimed At Treating Aggressive Cancerselicio Focuses On Harnessing The Natural Power Of Lymph Nodes To Enhance Immune Responses Against Tumorswith The Goal Of Improving Patient Outcomes The Company Utilizes Its Proprietary Amphiphileampplatform To Create Immunotherapies That Directly Target Lymph Nodespromoting The Activation And Proliferation Of Cancer Fighting T Cellselicio S Product Pipeline Includes Eli 002A Peptide Vaccine In Phase Ii Trials For Pancreatic Ductal Adenocarcinomaas Well As Eli 007 And Eli 008Which Target Specific Gene Mutations In Solid Tumorselicio Is Committed To Advancing Therapies Through Clinical Trialsemphasizing Precision Delivery And Sustained Immune Activation
